Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14222307 | 0.91 | TRPV6 (0.41) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL3038231 | 0.91 | GAA (0.49) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL3039081 | 0.89 | CCR2 (0.47) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL13222971 | 0.87 | CCR2 (0.41) | CCR2CYP2D6TSHRKCNH2ALDH1A1 | |
| SCHEMBL3023504 | 0.86 | CCR2 (0.47) | CCR2CYP2D6TSHRKCNH2KDM4E | |
| SCHEMBL3039147 | 0.86 | CYP2D6 (0.46) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL3035011 | 0.84 | CYP2D6 (0.46) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL13244006 | 0.83 | L3MBTL1 (0.52) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL3033580 | 0.83 | CCR2 (0.43) | CCR2CYP2D6TSHRKCNH2CACNA1G | |
| SCHEMBL3039150 | 0.83 | CCR2 (0.45) | CCR2CYP2D6TSHRKCNH2CACNA1G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | claimed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | EPIX DELAWARE, INC. (US) | 2010-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210633-A1 | CARBOXAMIDE COMPOUNDS AND THEIR USE | CCR2, CCR1, CCR5 | CCR2 1/4885CYP2D6 1241/4885TSHR 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.